Sign in

NCT07425925Completed

Digital Peer-support-based Anti-HIV Stigma Intervention Among Adolescents Living With HIV in Ethiopia

Feasibility and Effectiveness of Digital Peer-support-based Anti-HIV Stigma Intervention in Improving Clinical Outcomes Among Adolescents Living With HIV in Ethiopia

Source: ClinicalTrials.gov · Last updated 22 Oct 2026

Brief summary (registry, in English)

Advances in HIV care and treatment turned a once deadly disease into a chronic condition where people living with HIV, including perinatally HIV acquired children, can now lead a healthy life and live longer with their highly effective antiretroviral therapy. Despite the advancements and successes in HIV care and treatment, HIV-related stigma remained a challenge to people living with HIV and for the provision of the available successful treatment and support. Stigma and discrimination related to HIV infection inhibit health-seeking behaviour, clinical outcomes, physical and psychosocial wellbeing and is a major obstacle for timely diagnosis. Peer support programs to people living with HIV appeared to have improved self-confidence of members and consequently reduced self-stigma and improved their coping ability against external stigma. However, these services are limited in terms of geography owing to lack of adequate financing to cover operational costs for adolescents coming from rural areas and space and facility limitation to accommodate large groups. The eHealth services have potential to provide some of the services offered in the in-person sessions of the peer support group. Despite this important potential of eHealth services, they are underutilized and are not often used to target HIV-related stigma in adolescents living with HIV. The present study will investigate whether the digital peer-support anti-HIV stigma reduces internalized and anticipated stigma among adolescents living with HIV (ALHIV) in South Ethiopia. Further, we will explore the health-related outcomes including adolescent's psychological wellbeing, retention in care and sustained viral load suppression.

Status (registry)
Completed
Study type
Interventional
Enrollment
239 (actual)
First submitted
24 Nov 2025
Start date
13 Nov 2025
Primary completion date
20 Jun 2026
Lead sponsor
Lund University
Diseases
HIV
NCT number
NCT07425925

What you commit to

  • Study type: Interventional
  • Participants enrolled: 239
  • From 13 Nov 2025 to the primary completion date, 20 Jun 2026
  • 5 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Participants with known diagnosed mental health condition

Other

  • Participants with hearing loss or loss of vision

Who the study is looking for

  • Adolescents who have been disclosed of their HIV status
  • adolescents and young people between the age of 15 and 22 years old
  • receiving antiretroviral medications; and
  • completed at least first cycle primary school education (i.e. grade 4).

Age in the registry: 15 years to 22 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (5)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Arba Minch General Hospital
Coordinator of this site? Confirm its status
Arba MinchEthiopiaUnknown status
Dilla University Teaching Hospital
Coordinator of this site? Confirm its status
DaraEthiopiaUnknown status
Sawula General Hospital
Coordinator of this site? Confirm its status
GofaEthiopiaUnknown status
Jinka General Hospital
Coordinator of this site? Confirm its status
JinkaEthiopiaUnknown status
Wolaita Sodo University Comprehensive Specialized Hospital and Sodo Health Center
Coordinator of this site? Confirm its status
SodoEthiopiaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.